Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review and meta-analysis, the authors concluded that 5α-reductase inhibitor therapy is not consistently associated with significant increases in serum testosterone levels in men.

The researchers reported that non-motor symptoms like taste disorders and alopecia are associated with myasthenia gravis, particularly in severe cases and those linked to thymoma.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

This study identified known and potential novel adverse events, such as squamous cell carcinoma and dehydration, for vismodegib, underlining the importance of monitoring especially in the first two months of treatment.

In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.

This study identified numerous drugs with potential to trigger vitiligo, cautioning that these pharmacovigilance findings need further validation and that patients on these medications should be monitored for vitiligo development.

This review found that 5α‐reductase inhibitors were associated with slightly increased rates of decreased libido, erectile and ejaculatory dysfunction, gynecomastia, and mood disorders compared to placebo, though their long-term effects remain unclear.

This study revealed significant signals of drug-related cognitive disorders in several medications that lack relevant FDA label warnings, suggesting a need for increased clinical awareness and potential label updates.

In this study analyzing FDA data, researchers found that tralokinumab was associated with higher reports of conjunctivitis and keratitis compared to dupilumab, while dupilumab had more frequent injection site reactions, highlighting potential risks for clinical monitoring in atopic dermatitis treatments.

This study assessed the effectiveness of various combinations of minoxidil with other agents for androgenetic alopecia, finding that platelet-rich plasma and basic fibroblast growth factor combined with minoxidil significantly increased hair density, while different combinations were optimal depending on gender.

This study found that non-bleeding adverse events associated with NOACs affect multiple organ systems, emphasizing the importance of clinical vigilance. Specific NOACs like dabigatran, apixaban, edoxaban, and rivaroxaban were linked to distinct adverse reactions, including metabolic imbalances, thyroid disorders, and menstrual irregularities.

This study examined data from the FDA Adverse Event Reporting System and found that finasteride use is linked with both known and previously unlisted adverse events, such as erectile dysfunction and post-5α reductase inhibitor syndrome, with variations observed by age and sex.

This study found that while the global incidence of alopecia areata in individuals aged 0–19 declined from 1990-2021, the total number of cases rose, with higher burdens among females, adolescents, and low-SDI populations, particularly in Central Sub-Saharan Africa; disparities suggest a need for targeted interventions.

In this study, oral minoxidil treatment significantly increased serum VEGF levels and improved hair growth measures compared to a control group, suggesting its potential as an effective approach for promoting hair regrowth in androgenetic alopecia.

This study surveyed individuals seeking estrogen-based gender-affirming hormone therapy, revealing that improving life satisfaction and femininity are top treatment goals, and highlighting the need for trials aligned with community priorities.

This study found that pityriasis capitis was the most common skin disease among 507 hostellers in Pudukottai, followed by acne vulgaris and pediculosis capitis, with factors such as poor hygiene, lack of sunscreen use, junk food intake, and stress contributing to their prevalence.

This study analyzed gene expression data to identify key genes involved in severe forms of alopecia areata, discovering four immune monitoring genes (LGR5, SHISA2, HOXC13, S100A3) with potential for early diagnosis and better understanding of the disease's biological mechanisms.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study identified 193 plasma proteins associated with prostate cancer risk, validating 20 high-risk proteins including KLK3, and pinpointed potential drug targets like HSPB1, RRM2B, and PSCA through genetic analysis, offering new insights for biomarkers and treatments.

This study concluded that alopecia is a rare side effect of SSRIs, with sertraline showing a higher association compared to citalopram, particularly among women.

This study suggests that variations in PCOS phenotypes observed across different ethnic groups may be due to a genetic gradient resulting from historical human migrations and genetic drift.

This study confirmed that a sulfotransferase enzyme test can effectively rule out 95.9% of nonresponders to 5% topical minoxidil for treating androgenetic alopecia.

This study found an association between a splice site variant in the KRT71 gene and curly hair in Selkirk Rex cats, identifying a significant locus on chromosome B4.

This study found that hair follicle stem cells could enhance burn wound healing and improve tissue tensile strength in rats.

This study identified three symptom trajectory groups in individuals with PMDD, highlighting variations in symptom severity and duration across the luteal and follicular phases.

This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.

The CSTAR registry, the largest in China for SLE, reports more than 25,000 patients registered since 2009, detailing demographics, clinical characteristics, and providing data for future studies.

This study reports that the global age-standardized incidence and disability-adjusted life-year rates of alopecia areata decreased from 1990 to 2019, with the highest increases in incidence seen in some low SDI regions and countries like Kuwait and South Sudan.

This paper reviews the role of androgens in SARS-CoV-2 infection and their potential impact on disease severity, suggesting androgen-targeting strategies might influence outcomes, but reports no new clinical results.

In this study, researchers highlighted the high global prevalence of immune-related skin diseases like dermatitis and psoriasis, noting that females are disproportionately affected, emphasizing the need for tailored public health strategies based on sex and region.